Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 5:04 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Relief Product Placebo Control Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Radicle Relief 2: A Study of Health and Wellness Products on Pain and Health Outcomes

NCT05837923
View directory record Official record
Conditions
Pain, Neuropathic Pain, Nociceptive Pain
Interventions
Relief Active Study Product 1.1 Usage, Relief Active Study Product 1.2 Usage, Placebo Control Form 1, Relief Active Study Product 2.1 Usage, Placebo Control Form 2, Placebo Control Form 3, Relief Active Study Product 3.1 Usage, Relief Active Study Product 3.2 Usage, Relief Active Study Product 3.3 Usage
Dietary Supplement
Lead sponsor
Radicle Science
Industry
Eligibility
21 Years to 105 Years
Enrollment
2,016 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Del Mar, California
Source: ClinicalTrials.gov public record
Updated Oct 5, 2025 · Synced Sep 26, 2026, 5:04 AM EDT
Completed Phase 4 Interventional Results available

Effect of L-dopa In Subacute Back Pain Population

NCT01951105
View directory record Official record
Conditions
Sub-acute Back Pain
Interventions
Naproxen, Carbidopa/Levodopa, Placebo
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 23, 2021 · Synced Sep 26, 2026, 5:04 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Evaluating Postoperative Non-Opioid Pain Management Utilizing Local Anesthetics Coupled With Modulated Coagulation

NCT04814433
View directory record Official record
Conditions
Opioid Pain Medication
Interventions
Tranexamic acid, Aminocaproic acid, Recombinant Human Thrombin, Lidocaine Hydrochloride with Epinephrine, Bupivacaine Hydrochloride with Epinephrine
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 99 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 25, 2024 · Synced Sep 26, 2026, 5:04 AM EDT
Recruiting Phase 4 Interventional

NSAID Use for Treating Dysmenorrhea and Preventing Chronic Pelvic Pain (NSAID HEAL)

NCT06861920
View directory record Official record
Conditions
Dysmenorrhea, Chronic Pelvic Pain, Pelvic Pain
Interventions
Naproxen Sodium 550mg, Placebo, Extended Release Acetaminophen (650 mg)
Drug
Lead sponsor
Endeavor Health
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 6, 2025 · Synced Sep 26, 2026, 5:04 AM EDT
Completed Phase 3 Interventional Results available

A Study Comparing Two Fluticasone Furoate Nasal Sprays in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis

NCT01279057
View directory record Official record
Conditions
Rhinitis, Allergic, Seasonal
Interventions
Fluticasone furoate 27.5 mcg/actuation nasal spray (Lek Pharmaceuticals), Fluticasone furoate (Veramyst®) 27.5 mcg/actuation nasal spray, Placebo
Drug
Lead sponsor
Sandoz
Industry
Eligibility
12 Years and older
Enrollment
727 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
7
States / cities
Austin, Texas • Kerrville, Texas • New Braunfels, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2021 · Synced Sep 26, 2026, 5:04 AM EDT
Completed Not applicable Interventional Results available

The Effect of CSP01 on Chronic Idiopathic Constipation and Irritable Bowel Syndrome With Constipation

NCT03054506
View directory record Official record
Conditions
Constipation, Chronic Idiopathic Constipation, Irritable Bowel Syndrome With Constipation
Interventions
CSP01, Carboxymethylcellulose (CMC), Placebo
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
22 Years to 70 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 19, 2019 · Synced Sep 26, 2026, 5:04 AM EDT
Completed Phase 3 Interventional Results available

A Safety Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic Despite Treatment With H1 Antihistamines, H2 Blockers, and/or Leukotriene Receptor Antagonists

NCT01264939
View directory record Official record
Conditions
Chronic Idiopathic Urticaria
Interventions
Omalizumab, Placebo, H1 antihistamine, H2 antihistamine, leukotriene receptor antagonist, Diphenhydramine
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
12 Years to 75 Years
Enrollment
336 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
40
States / cities
Scottsdale, Arizona • Mission Viejo, California • Napa, California + 35 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2013 · Synced Sep 26, 2026, 5:04 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Assess Efficacy of an Experimental Oral Rinse in Providing Long Term Relief From Dentinal Hypersensitivity

NCT03238352
View directory record Official record
Conditions
Dentin Sensitivity
Interventions
Potassium oxalate, Sodium fluoride, Placebo
Device · Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
89 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Fort Wayne, Indiana
Source: ClinicalTrials.gov public record
Updated Nov 13, 2018 · Synced Sep 26, 2026, 5:04 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Radicle Relief RAL™: A Study Assessing the Impact of Health and Wellness Products on Pain Relief and Related Health Outcomes

NCT07262775
View directory record Official record
Conditions
Pain Interference
Interventions
Pain Relief Supplement Product Placebo Control, Pain Relief Supplement Active Product 1
Dietary Supplement
Lead sponsor
Radicle Science
Industry
Eligibility
21 Years to 105 Years
Enrollment
650 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Del Mar, California
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Sep 26, 2026, 5:04 AM EDT
Completed Phase 3 Interventional

Study to Compare the Therapeutic Equivalence of Mometasone Furoate Nasal Spray, 50 mcg With Nasonex Nasal Spray in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis

NCT02125253
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
Mometasone Furoate Nasal Spray, 50 mcg, Nasonex Nasal Spray, 50 mcg, Placebo Nasal Spray
Drug
Lead sponsor
Amneal Pharmaceuticals, LLC
Industry
Eligibility
12 Years and older
Enrollment
811 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
10
States / cities
Austin, Texas • Kerrville, Texas • New Braunfels, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2015 · Synced Sep 26, 2026, 5:04 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Cannabis Versus Oxycodone for Pain Relief

NCT02892591
View directory record Official record
Conditions
Back Pain, Neck Pain
Interventions
Cannabis, Oxycodone, Placebo for Cannabis, Placebo for Oxycodone
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
21 Years and older
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2023
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 21, 2024 · Synced Sep 26, 2026, 5:04 AM EDT
Completed Phase 3 Interventional Results available

A Study Comparing the Clinical Equivalence of Two Mometasone Nasal Sprays in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis

NCT01038427
View directory record Official record
Conditions
Rhinitis, Allergic, Seasonal
Interventions
Mometasone furoate 50 mcg/actuation nasal spray (Lek Pharmaceuticals), Mometasone furoate (Nasonex®) 50 mcg/actuation nasal spray, Placebo
Drug
Lead sponsor
Sandoz
Industry
Eligibility
12 Years and older
Enrollment
795 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
8
States / cities
Austin, Texas • Kerrville, Texas • Live Oak, Texas + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2021 · Synced Sep 26, 2026, 5:04 AM EDT
Completed Phase 3 Interventional

A Multicenter Study of Pseudoephedrine for the Temporary Relief of Nasal Congestion in Children With the Common Cold

NCT01744106
View directory record Official record
Conditions
Nasal Congestion Associated With the Common Cold
Interventions
pseudoephedrine hydrochloride 30 mg tablets, Placebo tablets
Drug
Lead sponsor
Perrigo Company
Industry
Eligibility
6 Years to 11 Years
Enrollment
565 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
11
States / cities
Anaheim, California • Costa Mesa, California • Boise, Idaho + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2016 · Synced Sep 26, 2026, 5:04 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of Hydrocodone Bitartrate Extended-Release Tablets (CEP-33237) for Relief of Moderate to Severe Pain in Patients With Osteoarthritis or Low Back Pain Who Require Opioid Treatment for an Extended Period of Time

NCT01240863
View directory record Official record
Conditions
Chronic Pain
Interventions
Hydrocodone ER, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
391 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
73
States / cities
Mobile, Alabama • Chandler, Arizona • Scottsdale, Arizona + 63 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2017 · Synced Sep 26, 2026, 5:04 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Hydrocodone Bitartrate Extended-Release Tablets for Moderate to Severe Chronic Low Back Pain

NCT01789970
View directory record Official record
Conditions
Low Back Pain
Interventions
Hydrocodone ER, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
625 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
87
States / cities
Anniston, Alabama • Birmingham, Alabama • Mobile, Alabama + 71 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2017 · Synced Sep 26, 2026, 5:04 AM EDT
Not yet recruiting Phase 3 Interventional

A Study of Intravenous L-Citrulline in Patients Aged 6-21 Years Old With Sickle Cell Disease Presenting to Emergency Departments in Acute Vaso-Occlusive Crisis

NCT06989567
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
L-citrulline, Placebo
Drug · Other
Lead sponsor
Asklepion Pharmaceuticals, LLC
Industry
Eligibility
6 Years to 21 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
6
States / cities
Washington D.C., District of Columbia • Coral Gables, Florida • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated May 28, 2025 · Synced Sep 26, 2026, 5:04 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Radicle Relief 1: A Study of Health and Wellness Products on Pain and Other Health Outcomes

NCT05589935
View directory record Official record
Conditions
Pain, Nociceptive Pain, Neuropathic Pain
Interventions
Relief Study Product Usage
Dietary Supplement
Lead sponsor
Radicle Science
Industry
Eligibility
21 Years to 105 Years
Enrollment
457 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Del Mar, California
Source: ClinicalTrials.gov public record
Updated Nov 21, 2023 · Synced Sep 26, 2026, 5:04 AM EDT
Completed Phase 3 Interventional Results available

Open-Label, Extension Study to Evaluate the Safety of Hydrocodone Bitartrate Extended-Release Tablets

NCT01922739
View directory record Official record
Conditions
Low Back Pain
Interventions
Hydrocodone ER, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
61
States / cities
Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 54 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2021 · Synced Sep 26, 2026, 5:04 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Radicle Relief 24_RLN: A Study Assessing the Impact of Health and Wellness Products on Pain and Related Health Outcomes.

NCT07160712
View directory record Official record
Conditions
Pain
Interventions
Relief Product Placebo Control, Relief Active Product 1, Relief Active Product 2, Relief Active Product 3
Dietary Supplement
Lead sponsor
Radicle Science
Industry
Eligibility
21 Years to 105 Years
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Del Mar, California
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Sep 26, 2026, 5:04 AM EDT
Completed Phase 4 Interventional Results available

Study of Triamcinolone Acetonide on the Growth Velocity of Children, Ages 3 to 9, With Perennial Allergic Rhinitis (PAR)

NCT00449072
View directory record Official record
Conditions
Rhinitis, Allergic, Perennial
Interventions
Placebo, TAA-AQ, Nasacort® AQ, Claritin®
Other · Drug
Lead sponsor
Sanofi
Industry
Eligibility
3 Years to 9 Years
Enrollment
299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 9, 2012 · Synced Sep 26, 2026, 5:04 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Dexlansoprazole Delayed-Release Capsules for Healing of Erosive Esophagitis and Maintenance of Healed Erosive Esophagitis and Relief of Heartburn in Adolescents

NCT01642615
View directory record Official record
Conditions
Gastroesophageal Reflux Disease, Erosive Esophagitis
Interventions
Dexlansoprazole, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
12 Years to 17 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
32
States / cities
Huntsville, Alabama • Mobile, Alabama • Phoenix, Arizona + 29 more
Source: ClinicalTrials.gov public record
Updated May 26, 2015 · Synced Sep 26, 2026, 5:04 AM EDT
Completed Phase 3 Interventional

Phase 3 Study to Compare the Efficacy and Safety of AR01 to a Placebo Solution for Relief of Pain in Acute Otitis Media

NCT02044341
View directory record Official record
Conditions
Acute Otitis Media
Interventions
AR01, Glycerin ear drops
Drug
Lead sponsor
Arbor Pharmaceuticals, Inc.
Industry
Eligibility
2 Months to 18 Years
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
29
States / cities
Sheffield, Alabama • Tuscon, Arizona • Jonesboro, Arkansas + 25 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2015 · Synced Sep 26, 2026, 5:04 AM EDT
Completed Not applicable Interventional Results available

Intraoperative and Post-operative Analgesic Effect of IV Acetaminophen for Sinus Surgery

NCT01608308
View directory record Official record
Conditions
Chronic Sinusitis
Interventions
IV Acetaminophen, Placebo
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 68 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 15, 2015 · Synced Sep 26, 2026, 5:04 AM EDT
Recruiting Phase 2 Interventional

Screening Trial for Pain Relief in Schwannomatosis (STARFISH)

NCT05684692
View directory record Official record
Conditions
Schwannomatosis, Schwannomas, Pain, Chronic
Interventions
Siltuximab, Erenumab-Aooe, Siltuximab Matching Placebo, Erenumab-Aooe Matching Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Sep 26, 2026, 5:04 AM EDT